Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 3 Oropharyngeal Neoplasms 3 Neoplasm Metastasis 3 Uterine Cervical Neoplasms 2 Sarcoma 2 Prostatic Neoplasms 2 Pheochromocytoma 2 Paraganglioma 2 Ovarian Neoplasms 2 Multiple Myeloma 2 Mouth Neoplasms 2 Melanoma 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Hodgkin Disease 2 Cholangiocarcinoma 2 Carcinoma, Hepatocellular 2 Anus Neoplasms 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Stage III Lung Non-Small Cell Cancer AJCC v7 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Rhabdoid Tumor 1 Rectal Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms 1

Interventions

Rituximab 13 Cyclophosphamide 9 Magnetic Resonance Spectroscopy 7 Lenalidomide 7 venetoclax 6 obinutuzumab 5 ibrutinib 5 Specimen Handling 5 fludarabine phosphate 4 fludarabine 4 Whole-Body Irradiation 4 Prednisone 4 CT-P10 4 Biopsy 4 zanubrutinib 3 orelabrutinib 3 Vincristine 3 Mycophenolic Acid 3 Cyclosporine 3 polatuzumab vedotin 2 pirtobrutinib 2 Tacrolimus 2 Peripheral Blood Stem Cell Transplantation 2 Doxorubicin 2 Busulfan 2 Bendamustine Hydrochloride 2 voruciclib 1 treosulfan 1 tafasitamab 1 prednylidene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, B-Cell, Marginal Zone × Fluorodeoxyglucose F18 × 90 days × Clear all

NCT06125028 2026-04-28

LYMFOR

Pentixapharm AG

Phase 3 Terminated

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon ⚡